Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 313

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 313
---
 Placement Warrant, each whole warrant entitling the holder thereof to purchase one Denali Class A Ordinary Share at an exercise price of $11.50 per share.

Expenses associated with the IPO totaled $1,150,000 which also included $650,000 of other operating expenses. Upon consummation of the IPO, Denali deposited $84,150,000 into the Trust Account for the benefit of the public shareholders and Maxim with respect to the deferred portion of its fee.

Prior to the consummation of the IPO, neither Denali nor anyone on its behalf, contacted any prospective target businesses or had any substantive discussions, formal or otherwise, with respect to a transaction with Denali. After the completion of the IPO, Denali commenced an active search for prospective business combination targets and considered numerous potential target businesses with the objective of consummating its initial business combination. Representatives of Denali contacted, and were contacted by, numerous individuals and entities who presented potential business combination opportunities.

On January 25, 2023, Denali entered into the Longevity Merger Agreement, by and among Longevity, Holdco, Denali-Longevity Merger Sub, Longevity Merger Sub, and the Seller Representative. Pursuant to the Longevity Merger Agreement, the parties thereto intended to enter into the Longevity Business Combination, pursuant to which, among other things, immediately following the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC, (i) the Denali-Longevity Merger would occur, with Denali as the surviving entity of the Denali-Longevity Merger, and (ii) the Longevity Merger would occur, with Longevity as the surviving company of the Longevity Merger. Afterwards, each of Longevity and Denali would be a subsidiary of Holdco, and Holdco would become a publicly traded company.

On January 9, 2024, Denali held the Longevity Business Combination Meeting and voted in favor of approving the Longevity Business Combination.

On May 13, 2024, according to Section 8.21 of the Longevity Merger Agreement, the Seller Representative informed Denali management that he received a written notice regarding the termination of one of the Cerevast Acquisition Agreement, the Aegeria Acquisition Agreement, and the Novokera Acquisition Agreement (each as defined in the Longevity Merger Agreement), with the possibility